Cell：癌症免疫疗法和靶向疗法联合治疗癌症（附原文）

hsu86

/ M! g$ X7 z8 o6 l

6 T* N9 R& o# o& k3 M近日，刊登在国际杂志Cell上的一篇研究论文中，来自德克萨斯大学MD安德森癌症中心的研究人员通过研究表示，利用免于免疫系统攻击癌症的药物同基因组靶向疗法相结合或许可以更好地帮助治疗癌症患者。5 o1 G  d. `$ \/ E. F8 c6 V

: t  n+ D, X! X. qImmune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential! v# R( C0 q+ S* @' }+ ^

% K4 @% E% k1 M* B, ~# j! x- [Padmanee Sharma, James P. Allison) W5 |; p! u; k8 S7 \8 }7 b

; q' k" U, c. z. i) K! N. {5 DResearch in two fronts has enabled the development of therapies that provide significant benefit to cancer patients. One area stems from a detailed knowledge of mutations that activate or inactivate signaling pathways that drive cancer development. This work triggered the development of targeted therapies that lead to clinical responses in the majority of patients bearing the targeted mutation, although responses are often of limited duration. In the second front are the advances in molecular immunology that unveiled the complexity of the mechanisms regulating cellular immune responses. These developments led to the successful targeting of immune checkpoints to unleash anti-tumor T cell responses, resulting in durable long-lasting responses but only in a fraction of patients. In this Review, we discuss the evolution of research in these two areas and propose that intercrossing them and increasing funding to guide research of combination of agents represent a path forward for the development of curative therapies for the majority of cancer patients.
" }! |9 [! x5 I
$ r: e/ R: U8 L5 @) D0 l/ ^5 c' i# ~! d" r# O, i
全文下载：5 S) u! T1 f5 n* {8 F& R

cyagen

cg001

谢谢